Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

NCT00784524 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Breast Cancer

Interventions

BIOLOGICAL: allogeneic large multivalent immunogen breast cancer vaccine
BIOLOGICAL: aldesleukin

Sponsor

Masonic Cancer Center, University of Minnesota